Relaxin, a pleiotropic vasodilator for the treatment of heart failure

Relaxin is a naturally occurring peptide hormone that plays a central role in the hemodynamic and renovascular adaptive changes that occur during pregnancy. Triggering similar changes could potentially be beneficial in the treatment of patients with heart failure. The effects of relaxin include the production of nitric oxide, inhibition of endothelin, inhibition of angiotensin II, production of VEGF, and production of matrix metalloproteinases. These effects lead to systemic and renal vasodilation, increased arterial compliance, and other vascular changes. The recognition of this has led to the study of relaxin for the treatment of heart failure. An initial pilot study has shown favorable hemodynamic effects in patients with heart failure, including reduction in ventricular filling pressures and increased cardiac output. The ongoing RELAX-AHF clinical program is designed to evaluate the effects of relaxin on the symptoms and outcomes in a large group of patients admitted to hospital for acute heart failure. This review will summarize both the biology of relaxin and the data supporting its potential efficacy in human heart failure.

• Publication year

  2008

• Venue

  Heart Failure Reviews

• Publication date

  2008-12-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10741-008-9129-3PMID 19101795PMCID 2772950
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial.

  2009cited by this paper
• The pathophysiology of acute heart failure--is it all about fluid accumulation?

  2008cited by this paper
• Negative cooperativity in H2 relaxin binding to a dimeric relaxin family peptide receptor 1.

  2008cited by this paper
• Fluid overload in acute heart failure — Re‐distribution and other mechanisms beyond fluid accumulation

  2008cited by this paper
• Acute decompensated heart failure and the cardiorenal syndrome

  2008cited by this paper
• Renal function during normal pregnancy and preeclampsia.

  2007cited by this paper
• The vascular actions of relaxin.

  2007cited by this paper
• Acute heart failure associated with high admission blood pressure — A distinct vascular disorder?

  2007cited by this paper
• Comparison of Signaling Pathways Activated by the Relaxin Family Peptide Receptors, RXFP1 and RXFP2, Using Reporter Genes

  2007cited by this paper
• The confounding issue of comorbid renal insufficiency.

  2006cited by this paper
• Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure.

  2006cited by this paper
• Relaxin Family Peptide Receptors RXFP1 and RXFP2 Modulate cAMP Signaling by Distinct Mechanisms

  2006cited by this paper
• Relaxin-a pleiotropic hormone and its emerging role for experimental and clinical therapeutics.

  2006cited by this paper
• Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor?

  2006cited by this paper
• Acute decompensated heart failure: the cardiorenal syndrome.

  2006cited by this paper
• Influence of recombinant human relaxin on renal hemodynamics in healthy volunteers.

  2006cited by this paper
• Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE).

  2005cited by this paper
• Relaxin Increases Cardiac Output and Reduces Systemic Arterial Load in Hypertensive Rats

  2005cited by this paper
• The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway.

  2005cited by this paper
• Effects of relaxin on systemic arterial hemodynamics and mechanical properties in conscious rats: sex dependency and dose response.

  2005cited by this paper
• Multiple Binding Sites Revealed by Interaction of Relaxin Family Peptides with Native and Chimeric Relaxin Family Peptide Receptors 1 and 2 (LGR7 and LGR8)

  2005cited by this paper
• Relationship between heart failure treatment and development of worsening renal function among hospitalized patients.

  2004cited by this paper
• Emerging role of relaxin in renal and cardiovascular function.

  2004cited by this paper
• Relaxin modifies systemic arterial resistance and compliance in conscious, nonpregnant rats.

  2004cited by this paper
• Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo.

  2004cited by this paper
• Time course and dose response of relaxin-mediated renal vasodilation, hyperfiltration, and changes in plasma osmolality in conscious rats.

  2003cited by this paper
• Phosphoinositide 3-kinase activity is required for biphasic stimulation of cyclic adenosine 3',5'-monophosphate by relaxin.

  2003cited by this paper
• N-terminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure

  2003cited by this paper
• Relaxin, a Pregnancy Hormone, Is a Functional Endothelin-1 Antagonist: Attenuation of Endothelin-1–Mediated Vasoconstriction by Stimulation of Endothelin Type-B Receptor Expression via ERK-1/2 and Nuclear Factor-&kgr;B

  2003cited by this paper
• Essential Role for Vascular Gelatinase Activity in Relaxin-Induced Renal Vasodilation, Hyperfiltration, and Reduced Myogenic Reactivity of Small Arteries

  2003cited by this paper
• Relaxin Gene and Protein Expression and Its Regulation of Procollagenase and Vascular Endothelial Growth Factor in Human Endometrial Cells1

  2002cited by this paper
• Acute heart failure: a novel approach to its pathogenesis and treatment

  2002cited by this paper
• Myogenic reactivity is reduced in small renal arteries isolated from relaxin-treated rats.

  2002cited by this paper
• Is the Pregnancy Hormone Relaxin Also a Vasodilator Peptide Secreted by the Heart?

  2002cited by this paper
• Relaxin activates the MAP kinase pathway in human endometrial stromal cells

  2002cited by this paper
• Activation of Orphan Receptors by the Hormone Relaxin

  2002influential reference
• The pregnancy hormone relaxin is a player in human heart failure

  2001cited by this paper
• Relaxin clinical trials in systemic sclerosis

  2001cited by this paper
• Flow-induced pressure differentially regulates endothelin-1, urotensin II, adrenomedullin, and relaxin in pulmonary vascular endothelium.

  2001cited by this paper
• The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction.

  2000cited by this paper
• Impact of gender and endothelin on renal vasodilation and hyperfiltration induced by relaxin in conscious rats.

  2000cited by this paper
• Relaxin is a potent renal vasodilator in conscious rats.

  1999cited by this paper
• Endothelin mediates renal vasodilation and hyperfiltration during pregnancy in chronically instrumented conscious rats.

  1999cited by this paper
• Relaxin may be the "elusive" renal vasodilatory agent of normal pregnancy.

  1999cited by this paper
• Relaxin stimulates expression of vascular endothelial growth factor in normal human endometrial cells in vitro and is associated with menometrorrhagia in women.

  1999cited by this paper
• Endothelin mediates renal vasodilation and hyperfiltration during pregnancy in chronically instrumented conscious rats.

  1999cited by this paper
• Identification of specific relaxin-binding cells in the human female.

  1998cited by this paper
• Demonstration of a relaxin receptor and relaxin-stimulated tyrosine phosphorylation in human lower uterine segment fibroblasts.

  1998cited by this paper
• Relaxin activates the L-arginine-nitric oxide pathway in vascular smooth muscle cells in culture.

  1998cited by this paper
• Contribution of endogenous endothelin-1 to the maintenance of vascular tone: role of nitric oxide.

  1997cited by this paper
• Relaxin stimulates atrial natriuretic peptide secretion in perfused rat heart.

  1996cited by this paper
• Acute blockade of nitric oxide synthase inhibits renal vasodilation and hyperfiltration during pregnancy in chronically instrumented conscious rats.

  1995cited by this paper
• Relaxin‐induced increased coronary flow through stimulation of nitric oxide production

  1995cited by this paper
• Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts.

  1990cited by this paper
• Blunted Responses to Vasoconstrictors in Mesenteric Vasculature but not in Portal Vein of Spontaneously Hypertensive Rats Treated with Relaxin

  1989cited by this paper
• Pregnancy: an overfill or underfill state.

  1987cited by this paper
• SERIAL CHANGES IN 24 HOUR CREATININE CLEARANCE DURING NORMAL MENSTRUAL CYCLES AND THE FIRST TRIMESTER OF PREGNANCY

  1981cited by this paper
• Effects of relaxin on the endothelium of endometrial blood vessels in monkeys (Macaca mulatta).

  1967cited by this paper
• THE RELAXATIVE HORMONE OF THE CORPUS LUTEUM. ITS PURIFICATION AND CONCENTRATION1

  1930cited by this paper
• The FASEB Journal • Research Communication Evidence for local relaxin ligand-receptor expression and function in arteries

  year unknowncited by this paper

• The Discovery of C7-Substituted Norbornyl Bisamides as RXFP1 Small Molecule Agonists.

  2025cites this paper
• The involvement of the Wnt/β-catenin signaling cascade in fibrosis progression and its therapeutic targeting by relaxin.

  2024cites this paper
• End‐organ protective effect of serelaxin in patients hospitalized for heart failure: Results of the biomarker substudy of Relaxin in Acute Heart Failure‐2 (RELAX‐AHF‐2)

  2024cites this paper
• Multi-trait analysis characterizes the genetics of thyroid function and identifies causal associations with clinical implications

  2024cites this paper
• Development of a long‐acting relaxin analogue, LY3540378, for treatment of chronic heart failure

  2023cites this paper
• Further Developments towards a Minimal Potent Derivative of Human Relaxin-2

  2023cites this paper
• Identification of Significant Proteins in Hypertension Using The Clustering Molecular Complex Detection (MCODE) Method

  2023cites this paper
• Cardiovascular effects of relaxin-2: therapeutic potential and future perspectives

  2023cites this paper
• The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy.

  2023cites this paper
• Preconceptional and Periconceptional Pathways to Preeclampsia

  2022cites this paper
• Mechanisms of Cardiorenal Protection With SGLT2 Inhibitors in Patients With T2DM Based on Network Pharmacology

  2022cites this paper
• Untangling the Cooperative Role of Nuclear Receptors in Cardiovascular Physiology and Disease

  2021cites this paper
• Potential Role of the Corpus Luteum in Maternal Cardiovascular Adaptation to Pregnancy, and Preeclampsia Risk.

  2021cites this paper
• Relaxin Inhibits Ventricular Arrhythmia and Asystole in Rats With Pulmonary Arterial Hypertension

  2021cites this paper
• Serelaxin activates eNOS, suppresses inflammation, attenuates developmental delay and improves cognitive functions of neonatal rats after germinal matrix hemorrhage

  2020cites this paper
• Relaxin and the Cardiovascular System: From Basic Science to Clinical Practice.

  2020cites this paper
• A Strategy To Prepare Peptide Heterodimers in the Solid Phase with an Acid-Labile Linker.

  2019cites this paper
• A model for positive feedback control of the transformation of fibroblasts to myofibroblasts.

  2019cites this paper
• Intraarticular injection of relaxin-2 alleviates shoulder arthrofibrosis

  2019cites this paper
• Relaxin 2 fails to lower intraocular pressure and to dilate retinal vessels in rats

  2019cites this paper
• Trans-ethnic association study of blood pressure determinants in over 750,000 individuals

  2018cites this paper
• Optimization of the first small-molecule relaxin/insulin-like family peptide receptor (RXFP1) agonists: Activation results in an antifibrotic gene expression profile.

  2018cites this paper
• Transcriptional up-regulation of relaxin-3 by Nur77 attenuates β-adrenergic agonist–induced apoptosis in cardiomyocytes

  2018cites this paper
• Design and Synthesis of Potent, Long-Acting Lipidated Relaxin-2 Analogs.

  2018cites this paper
• Trans-ethnic association study of blood pressure determinants in over 750 , 000 individuals 1

  2018cites this paper
• The relaxin receptor as a therapeutic target – perspectives from evolution and drug targeting

  2018cites this paper
• Transcriptional up-regulation of relaxin-3 by Nur77 attenuates (cid:2) -adrenergic agonist–induced apoptosis in cardiomyocytes

  2018cites this paper
• Effects of serelaxin on renal microcirculation in rats under control and high-angiotensin environments.

  2018cites this paper
• Pregnancy-Related Hormonal Influences on the Musculoskeletal System, Lumbo-Pelvic Structures and Peripheral Joints: Some Practical Considerations for Manual Therapists

  2017cites this paper
• Serelaxin improves cardiac and renal function in DOCA-salt hypertensive rats

  2017cites this paper
• The evolution of heart failure with reduced ejection fraction pharmacotherapy: What do we have and where are we going?

  2017cites this paper
• Serelaxin in clinical development: past, present and future

  2017influential citation
• Anti‐fibrotic actions of relaxin

  2017cites this paper
• Herzinsuffizienz: Akuttherapie mit Ularitide verbessert nicht die Prognose

  2017cites this paper
• Anti-atherosclerotic effects of serelaxin in apolipoprotein E-deficient mice.

  2016cites this paper
• Cardiovascular effects of the sirtuin and urocortin systems in humans

  2016cites this paper
• Novel Therapies for the Prevention and Management of Acute Decompensated Heart Failure

  2016cites this paper
• Nouveaux médicaments dans l’insuffisance cardiaque aiguë

  2016cites this paper
• Relaxin: A novel therapy for acute heart failure.

  2016cites this paper
• Organ protection possibilities in acute heart failure.

  2016cites this paper
• Recombinant human relaxin versus placebo for cervical ripening: a double-blind randomised trial in pregnant women scheduled for induction of labour

  2016cites this paper
• Relaxin-2 improves diastolic function of pressure-overloaded rats via phospholamban by activating Akt.

  2016cites this paper
• Nesiritide in patients hospitalized for acute heart failure: does timing matter? Implication for future acute heart failure trials

  2016cites this paper
• Organ protection possibilities in acute heart failure.

  2016cites this paper
• A common effect of angiotensin II and relaxin 2 on the PNT1A normal prostate epithelial cell line

  2016cites this paper
• Vasoprotective actions of relaxin in the vascular system

  2016cites this paper
• International Union of Basic and Clinical Pharmacology. XCV. Recent Advances in the Understanding of the Pharmacology and Biological Roles of Relaxin Family Peptide Receptors 1–4, the Receptors for Relaxin Family Peptides

  2015cites this paper
• Agents with vasodilator properties in acute heart failure: how to design successful trials

  2015cites this paper
• Effect of Serelaxin on Mode of Death in Acute Heart Failure Results From the RELAX-AHF Study

  2015cites this paper
• Pharmacokinetics of serelaxin in patients with hepatic impairment: a single-dose, open-label, parallel group study.

  2015cites this paper
• Effect of Serelaxin on Mode of Death in Acute Heart Failure Results From the RELAX-AHF Study

  2015cites this paper
• Novel markers and therapies for patients with acute heart failure and renal dysfunction.

  2015cites this paper
• Renal impairment and worsening of renal function in acute heart failure: can new therapies help? The potential role of serelaxin

  2015cites this paper
• Relaxin: A Novel Agent for the Treatment of Acute Heart Failure

  2015cites this paper
• Early Medical Management of Hospitalization for Heart Failure (HHF)

  2015cites this paper
• Ularitide: a natriuretic peptide candidate for the treatment of acutely decompensated heart failure.

  2015cites this paper
• Serelaxin for the treatment of acute heart failure: a review with a focus on end-organ protection

  2015cites this paper
• Pharmacological treatment of left ventricular remodeling: recent trial results

  2015cites this paper
• Mode of Death Prevention by Serelaxin.

  2015cites this paper
• Chapter 16 – The Kidney in Normal Pregnancy and Preeclampsia

  2015cites this paper
• New Drugs You are Going to Read About: Serelaxin, Ularitide, TRV027

  2015cites this paper
• Targeted biological therapies reach the heart: the case of serelaxin for heart failure.

  2015cites this paper
• Diagnosis and management of acute heart failure

  2015cites this paper
• Reply: Mode of Death Prevention by Serelaxin.

  2015cites this paper
• Neue Medikamente in der Kardiologie

  2014cites this paper
• Hormones and Hemodynamics in Pregnancy

  2014cites this paper
• The renal circulation in normal pregnancy and preeclampsia: is there a place for relaxin?

  2014cites this paper
• The Role of Intravenous Vasodilators in Acute Heart Failure Management

  2014cites this paper
• Serelaxin: a potential new drug for the treatment of acute heart failure

  2014cites this paper
• The effect of long-term diabetes mellitus induced by treatment with streptozotocin in 6-week-old rats on functional activity of the adenylyl cyclase system

  2014cites this paper
• Serelaxin: A Novel Therapy for Acute Heart Failure with a Range of Hemodynamic and Non-Hemodynamic Actions

  2014cites this paper
• Vasodilators in Acute Heart Failure: Review of the Latest Studies

  2014cites this paper
• Detection of relaxin receptor in the dorsoradial ligament, synovium, and articular cartilage of the trapeziometacarpal joint

  2014cites this paper
• Serelaksyna — czy mamy przełom w leczeniu ostrej niewydolności serca? Wyniki badania RELAX-AHF

  2014cites this paper
• Quantification of recombinant human relaxin-2 (B-29/A-24) in non-pregnant rat plasma using ultra performance liquid chromatography-mass spectrometry

  2014cites this paper
• [New pharmaceuticals in cardiology. Heart failure, anticoagulation, dyslipidemia].

  2014cites this paper
• Effect of serelaxin on mode of death in acute heart failure: results from the RELAX-AHF study.

  2014cites this paper
• Apelin and Relaxin Plasma Levels in Young Healthy Offspring of Patients With Essential Hypertension

  2014cites this paper
• Increased Mortality after an Acute Heart Failure Episode: New Pathophysiological Insights from the RELAX-AHF Study and Beyond

  2014cites this paper
• Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF

  2013influential citation
• Acute Heart Failure Treatment

  2013cites this paper
• Serelaxin, a 'breakthrough' investigational intravenous agent for acute heart failure.

  2013cites this paper
• The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.

  2013cites this paper
• Relaxin family peptides and their receptors.

  2013cites this paper
• Relaxin Suppresses Atrial Fibrillation by Reversing Fibrosis and Myocyte Hypertrophy and Increasing Conduction Velocity and Sodium Current in Spontaneously Hypertensive Rat Hearts

  2013cites this paper
• Renal effects of vasodilators in acute heart failure

  2013cites this paper
• Masked Hypertension and Atherogenesis: The Impact of Apelin and Relaxin Plasma Levels

  2013cites this paper
• GPCR biased ligands as novel heart failure therapeutics.

  2013cites this paper
• The role of the relaxin receptor RXFP1 in brain cancer

  2013cites this paper
• Relaxin for Treatment of Acute Heart Failure: Making the Case for Treating Targeted Patient Profiles

  2013cites this paper
• RELAX-AHF: consistency across subgroups and new hypotheses generated.

  2013cites this paper
• Emergency Department Therapy of Acute Heart Failure

  2012cites this paper
• Relaxin promotes growth and maturation of mouse neonatal cardiomyocytes in vitro: clues for cardiac regeneration

  2012cites this paper
• Can we prevent or treat renal dysfunction in acute heart failure?

  2012cites this paper
• Relaxin-2 may offer therapeutic advantages in end-stage heart failure.

  2012cites this paper
• Management of the Cardiorenal Syndrome in Acute Heart Failure

  2012cites this paper
• himeric relaxin peptides highlight the role of the A-chain in the function of H 2 elaxin ohammed

  2012cites this paper
• Treating volume overload in acutely decompensated heart failure: established and novel therapeutic approaches

  2012cites this paper
• Relaxin Signals through a RXFP1-pERK-nNOS-NO-cGMP-Dependent Pathway to Up-Regulate Matrix Metalloproteinases: The Additional Involvement of iNOS

  2012cites this paper
• Angiogenic Growth Factors Are New and Essential Players in the Sustained Relaxin Vasodilatory Pathway in Rodents and Humans

  2011cites this paper